CureVac NV Net Income Over Time
| CVAC Stock | USD 4.66 0.00 0.00% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. Will Biotechnology sector continue expanding? Could CureVac diversify its offerings? Factors like these will boost the valuation of CureVac NV. Projected growth potential of CureVac fundamentally drives upward valuation adjustments. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every CureVac NV data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Quarterly Earnings Growth 0.24 | Earnings Share 0.67 | Revenue Per Share | Quarterly Revenue Growth (0.89) | Return On Assets |
The market value of CureVac NV is measured differently than its book value, which is the value of CureVac that is recorded on the company's balance sheet. Investors also form their own opinion of CureVac NV's value that differs from its market value or its book value, called intrinsic value, which is CureVac NV's true underlying value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Because CureVac NV's market value can be influenced by many factors that don't directly affect CureVac NV's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between CureVac NV's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding CureVac NV should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, CureVac NV's quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Cross Equities Net Income Analysis
Compare CureVac NV and related stocks such as Novavax, Nektar Therapeutics, and Syndax Pharmaceuticals Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NVAX | (5.5 M) | (19.4 M) | (28.5 M) | (52 M) | (82.9 M) | (156.9 M) | (280 M) | (183.8 M) | (184.7 M) | (130.1 M) | (427.5 M) | (1.7 B) | (657.9 M) | (545.1 M) | (187.5 M) | (168.7 M) | (177.2 M) |
| NKTR | (5.3 M) | (134 M) | (171.9 M) | (162 M) | (53.9 M) | (81.2 M) | (153.5 M) | (96.7 M) | 681.3 M | (440.7 M) | (444.4 M) | (523.8 M) | (368.2 M) | (276.1 M) | (119 M) | (107.1 M) | (112.4 M) |
| SNDX | (13.1 M) | (13.1 M) | (10 M) | (14.2 M) | (19.8 M) | (24.1 M) | (44.5 M) | (60.8 M) | (74 M) | (56 M) | (73.1 M) | 24.9 M | (143.7 M) | (209.4 M) | (318.8 M) | (286.9 M) | (272.5 M) |
| INBX | (8.3 M) | (8.3 M) | (8.3 M) | (8.3 M) | (8.3 M) | (8.3 M) | (8.3 M) | (19.4 M) | (31.2 M) | (51.4 M) | (75.6 M) | (81.8 M) | (145.2 M) | (241.4 M) | 1.7 B | 1.9 B | 2 B |
| IMTX | (31.4 M) | (31.4 M) | (31.4 M) | (31.4 M) | (31.4 M) | (31.4 M) | (31.4 M) | (31.4 M) | (31.4 M) | (31.7 M) | (229.3 M) | (95.1 M) | 37.5 M | (97 M) | 15.2 M | 17.5 M | 18.4 M |
| RLAY | (48.8 M) | (48.8 M) | (48.8 M) | (48.8 M) | (48.8 M) | (48.8 M) | (48.8 M) | (48.8 M) | (48.8 M) | (66.5 M) | (52.4 M) | (363.9 M) | (290.5 M) | (342 M) | (337.7 M) | (303.9 M) | (319.1 M) |
| ORIC | (22 M) | (22 M) | (22 M) | (22 M) | (22 M) | (22 M) | (22 M) | (22 M) | (21.4 M) | (26.9 M) | (73.7 M) | (77.7 M) | (89.1 M) | (100.7 M) | (127.8 M) | (115.1 M) | (109.3 M) |
| ELVN | (11.3 M) | (11.3 M) | (11.3 M) | (11.3 M) | (11.3 M) | (11.3 M) | (11.3 M) | (11.3 M) | (11.3 M) | (23.5 M) | (19 M) | (24.7 M) | (37.7 M) | (71.6 M) | (89 M) | (80.1 M) | (76.1 M) |
CureVac NV and related stocks such as Novavax, Nektar Therapeutics, and Syndax Pharmaceuticals Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in CureVac NV financial statement analysis. It represents the amount of money remaining after all of CureVac NV operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.My Equities
My Current Equities and Potential Positions
| CureVac NV | CVAC |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Business Address | Friedrich-Miescher-Strasse 15, Tbingen, |
| Exchange | NASDAQ Exchange |
USD 4.66
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. You can also try the Transaction History module to view history of all your transactions and understand their impact on performance.
CureVac NV technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.